1. Integrating liquid biopsy analysis for advanced non–invasive cancer diagnosis and management
2. Mutation profiles analysis of Thai cholangiocarcinoma patients in tissue, blood cfDNA, and bile cfDNA Samples
3. Study of the molecular mechanism of IMPDH2 involved in metastasis of osteosarcoma
4. Proteomic analysis of archived formalin–fixed paraffin–embedded tissues for identification of predictive biomarker for non–small cell lung cancer recurrence

Research Interests 

The research of the Cancer Research Unit (CRU) is based on real-world questions from healthcare professionals and has been developed in cooperation with experts in various fields. We attempt to link basic research with clinical problems in order to advance precision medicine in cancer therapy through an in-depth understanding of the disease at the molecular level.

CRU focuses on the development of effective pipelines for analyzing cancer-relevant analyses in “Liquid Biopsy” with a particular emphasis on cfDNA size distribution and circulating tumor cell (CTC) subtype characterization. Further work on the mechanisms of aberration in cfDNA fragmentomics and the single-cell profiling of CTCs is under way with advanced techniques in molecular oncology and bioinformatics.

Furthermore, to overcome drug resistance and metastasis, we focus our research on tumour heterogeneity, tumor microenvironment, and tumour evolution through multi-omic analysis of biological specimens to discover novel targets for cancer treatment. We are also developing an effective workflow for sample preparation for proteomic analysis of a variety of biological specimens.

Publications 

1. Udomruk, S., Phanphaisarn, A., Kanthawang, T., Sangphukieo, A., Sutthitthasakul, S., Tongjai, S., Teeyakasem, P., Thongkumkoon, P., Orrapin, S., Moonmuang, S., Klangjorhor, J., Pasena, A., Suksakit, P., Dissook, S., Puranachot, P., Settakorn, J., Pusadee, T., Pruksakorn, D., & Chaiyawat, P. (2023). Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients. Clin Cancer Res, 29(11), 2085-2094.
2. Moonmuang, S., Tantraworasin, A., Orrapin, S., Udomruk, S., Chewaskulyong, B., Pruksakorn, D., & Chaiyawat, P. (2023). The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer. Int J Mol Sci, 24(5).
3. Sirikaew, N., Pruksakorn, D., Chaiyawat, P., & Chutipongtanate, S. (2022). Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction. Int J Mol Sci, 23(17).
4. Orrapin, S., Udomruk, S., Lapisatepun, W., Moonmuang, S., Phanphaisarn, A., Phinyo, P., Pruksakorn, D., & Chaiyawat, P. (2022). Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers (Basel), 14(14).
5. Udomruk, S., Orrapin, S., Pruksakorn, D., & Chaiyawat, P. (2021). Size distribution of cell-free DNA in oncology. Crit Rev Oncol Hematol, 166, 103455.
6. Chaiyawat, P., Phanphaisarn, A., Sirikaew, N., Klangjorhor, J., Thepbundit, V., Teeyakasem, P., Phinyo, P., Pruksakorn, D., & Settakorn, J. (2021). IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma. Sci Rep, 11(1), 10887.
7. Chaiyawat, P., Sirikaew, N., Budprom, P., Klangjorhor, J., Phanphaisarn, A., Teeyakasem, P., Settakorn, J., & Pruksakorn, D. (2020). Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma. J Bone Oncol, 25, 100321.
8. Chaiyawat, P., Pruksakorn, D., Pipatwattana, P., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2019). Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma. J Bone Oncol, 16, 100233.
9. Chaiyawat, P., Sungngam, P., Teeyakasem, P., Sirikaew, N., Klangjorhor, J., Settakorn, J., Diskul-Na-Ayudthaya, P., Chokchaichamnankit, D., Srisomsap, C., Svasti, J., & Pruksakorn, D. (2019). Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway. Int J Oncol, 54(5), 1704-1718.
10. Chaiyawat, P., Pruksakorn, D., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2018). Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications. Mod Pathol, 31(2), 264-274.
11. Chaiyawat, P., Klangjorhor, J., Settakorn, J., Champattanachai, V., Phanphaisarn, A., Teeyakasem, P., Svasti, J., & Pruksakorn, D. (2017). Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma. Transl Oncol, 10(5), 846-853.
12. Chaiyawat, P., Settakorn, J., Sangsin, A., Teeyakasem, P., Klangjorhor, J., Soongkhaw, A., & Pruksakorn, D. (2017). Exploring targeted therapy of osteosarcoma using proteomics data. Onco Targets Ther, 10, 565-577.
13. Chaiyawat, P., Weeraphan, C., Netsirisawan, P., Chokchaichamnankit, D., Srisomsap, C., Svasti, J., & Champattanachai, V. (2016). Elevated O-GlcNAcylation of Extracellular Vesicle Proteins Derived from Metastatic Colorectal Cancer Cells. Cancer Genomics Proteomics, 13(5), 387-398.
14. Chaiyawat, P., Chokchaichamnankit, D., Lirdprapamongkol, K., Srisomsap, C., Svasti, J., & Champattanachai, V. (2015). Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells. Oncol Rep, 34(4), 1933-1942.
15. Chaiyawat, P., Netsirisawan, P., Svasti, J., & Champattanachai, V. (2014). Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer. Front Endocrinol (Lausanne), 5, 193.

Address  :  9^th floor – The 50^th Anniversary Building, Faculty of Medicine, Chiang Mai University, 110 Intawaroros Road, Si Phum, Muang, Chiang Mai 50200

Email  :  parunya.chaiyawat@cmu.ac.th

Organizations  :  Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM)